For Healthcare Professionals

Cellular Immunotherapy for Immune Tolerance in Past Recipients of HLA Zero-mismatch, Living Donor Kidney Transplants

clipboard-pencil

About the study

The primary objective of this study is to demonstrate the safety and efficacy of cellular immunotherapy with MDR-103 for induction of functional immune tolerance in past recipients of human leukocyte antigen (HLA)-matched, living donor kidney transplants.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

Recipient Inclusion Criteria:

  1. Past recipient of a first kidney allograft from an HLA-matched, living related donor
  2. Age ≥18 and ≤70 years
  3. Single solid organ recipient (kidney only)
  4. ABO compatibility with donor

Donor Inclusion Criteria:

  1. HLA-matched first degree (parent, child or sibling) or second-degree (child of a sibling, half sibling) relative of the prospective recipient participant
  2. Age ≥18 and ≤70 years
  3. Past living related kidney donor, and capable of undergoing G-CSF mobilization and apheresis of hematopoietic cells

EXCLUSION CRITERIA

Exclusion Criteria:

Recipient Exclusion Criteria:

  1. Underlying kidney disease with a high risk of disease recurrence in the transplanted kidney
  2. Baseline positive donor-specific anti-HLA antibody testing
  3. Is taking immunosuppressive therapy
  4. Evidence of prior hepatitis B (HBV) or hepatitis C (HCV)

Donor Exclusion Criteria:

  1. History of autoimmune disorders
  2. History of type 1 or type 2 diabetes mellitus
  3. Tests confirmed positive for human immunodeficiency virus (HIV), HBV, HCV
  4. History of infection with Zika virus
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition

Kidney Transplant Rejection

Age (in years)

18 - 70

Phase

Phase 2

Participants needed

25

Est. Completion Date

Oct 31, 2025

Treatment type

Interventional


Sponsor

Medeor Therapeutics, Inc.

ClinicalTrials.gov identifier

NCT03606746

Study number

MDR-103-L2K

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.